{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T13:05:19Z","timestamp":1792847119388,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,20]]},"DOI":"10.7759\/cureus.88350","type":"journal-article","created":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T08:43:17Z","timestamp":1753000997000},"source":"Crossref","is-referenced-by-count":7,"title":["Semaglutide-Induced Small Bowel Pseudo-Obstruction and Ileitis in a Patient With Type 2 Diabetes: A Case Report"],"prefix":"10.7759","author":[{"given":"Faiza","family":"Javed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman A. A","family":"Shaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samson O","family":"Oyibo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Diabetes-type 2. prevalence. (2025). Accessed: June 11, 2025: https:\/\/cks.nice.org.uk\/topics\/diabetes-type-2\/background-information\/prevalence\/."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/653789","article-title":"Impact of diabetes on cardiovascular disease: an update","volume":"2013","author":"Matheus AS","year":"2013","unstructured":"Matheus AS, Tannus LR, Cobas RA, Palma CC, Negrato CA, Gomes MB. Impact of diabetes on cardiovascular disease: an update. Int J Hypertens. 2013, 2013:653789. 10.1155\/2013\/653789","journal-title":"Int J Hypertens"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 siabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Open Access","volume":"38","author":"Inzucchi SE","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al.. Management of hyperglycemia in type 2 siabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Open Access. Diabetes Care. 2015, 38:140-9. 10.2337\/dc14-2441","journal-title":"Diabetes Care"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-018-0800-2","article-title":"GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data","volume":"17","author":"Sposito AC","year":"2018","unstructured":"Sposito AC, Berwanger O, de Carvalho LSF, Saraiva JFK. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. Cardiovasc Diabetol. 2018, 17:157. 10.1186\/s12933-018-0800-2","journal-title":"Cardiovasc Diabetol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.59965","article-title":"GLP-1 receptor agonists (GLP- 1RAs): cardiovascular actions and therapeutic potential","volume":"17","author":"Ma X","year":"2021","unstructured":"Ma X, Liu Z, Ilyas I, et al.. GLP-1 receptor agonists (GLP- 1RAs): cardiovascular actions and therapeutic potential. Int J Biol Sci. 2021, 17:2050-68. 10.7150\/ijbs.59965","journal-title":"Int J Biol Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"330","author":"Sodhi M","year":"2023","unstructured":"Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA. 2023, 330:1795-7. 10.1001\/jama.2023.19574","journal-title":"JAMA"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2430","article-title":"Incretin-based drugs and risk of intestinal obstruction among patients with type 2 diabetes","volume":"111","author":"Faillie JL","year":"2022","unstructured":"Faillie JL, Yin H, Yu OHY, Herrero A, Altwegg R, Renoux C, Azoulay L. Incretin-based drugs and risk of intestinal obstruction among patients with type 2 diabetes. Clin Pharmacol Ther. 2022, 111:272-82. 10.1002\/cpt.2430","journal-title":"Clin Pharmacol Ther"},{"key":"ref8","unstructured":"World Health Organisation (WHO)-Uppsala Monitoring Centre (UMC). The use of the WHO-UMC system for standardised case causality assessment. (2013). Accessed: July 16, 2025: https:\/\/www.who.int\/publications\/m\/item\/WHO-causality-assessment."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1299","article-title":"Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study","volume":"35","author":"Diabetes Prevention Program Research Group","year":"2012","unstructured":"Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2012, 35:731-7. 10.2337\/dc11-1299","journal-title":"Diabetes Care"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000617","article-title":"Fecal calprotectin for the diagnosis and management of inflammatory bowel diseases","volume":"14","author":"Kapel N","year":"2023","unstructured":"Kapel N, Ouni H, Benahmed NA, Barbot-Trystram L. Fecal calprotectin for the diagnosis and management of inflammatory bowel diseases. Clin Transl Gastroenterol. 2023, 14:00617. 10.14309\/ctg.0000000000000617","journal-title":"Clin Transl Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i30.5634","article-title":"Acute colonic pseudo-obstruction: a systematic review of aetiology and mechanisms","volume":"23","author":"Wells CI","year":"2017","unstructured":"Wells CI, O'Grady G, Bissett IP. Acute colonic pseudo-obstruction: a systematic review of aetiology and mechanisms. World J Gastroenterol. 2017, 23:5634-44. 10.3748\/wjg.v23.i30.5634","journal-title":"World J Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng Z","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, Gao J. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024, 9:234. 10.1038\/s41392-024-01931-z","journal-title":"Signal Transduct Target Ther"},{"key":"ref13","article-title":"Semaglutide induced gastric outlet obstruction: a case report","volume":"45","author":"Shemies RS","year":"2022","unstructured":"Shemies RS, Abdalbary M, Nasreldin EK, Fouda AY, AbdelRazik A, Alsulaimani AA, Abdelsalam M. Semaglutide induced gastric outlet obstruction: a case report. Teikyo Med J. 2022, 45:6743-8.","journal-title":"Teikyo Med J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvad114.123","article-title":"SAT675 GLP-1RA therapy and intussusception: a case report of bowel telescoping in an obese patient after successful weight loss on therapy","volume":"7","author":"Alqaisi S","year":"2023","unstructured":"Alqaisi S, Doerfler WR, Latif T, Bandi A. SAT675 GLP-1RA therapy and intussusception: a case report of bowel telescoping in an obese patient after successful weight loss on therapy. J Endocr Soc. 2023, 7:bvad114.123. 10.1210\/jendso\/bvad114.123","journal-title":"J Endocr Soc"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.acepjo.2025.100045","article-title":"A case of intussusception with bowel obstruction in a gastric Roux-en-Y patient prescribed semaglutide","volume":"6","author":"Pavuluri SK","year":"2025","unstructured":"Pavuluri SK, Toumar A, Duffy AJ. A case of intussusception with bowel obstruction in a gastric Roux-en-Y patient prescribed semaglutide. J Am Coll Emerg Physicians Open. 2025, 6:100045. 10.1016\/j.acepjo.2025.100045","journal-title":"J Am Coll Emerg Physicians Open"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/389522-semaglutide-induced-small-bowel-pseudo-obstruction-and-ileitis-in-a-patient-with-type-2-diabetes-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T08:43:18Z","timestamp":1753000998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/389522-semaglutide-induced-small-bowel-pseudo-obstruction-and-ileitis-in-a-patient-with-type-2-diabetes-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,20]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.88350","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,20]]}}}